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Conclusion: Dose escalated radiotherapy for node positive 
locally advanced cervical cancer at primary diagnosis or at 
nodal recurrence using a SIB results in acceptable rates of 
acute and late toxicity. And although our small size 
population, the present results contribute that the SIB 
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Purpose or Objective: To determine the maximum tolerated 
dose (MTD) and dose-limiting toxicity (DLT) of weekly PTX 
and DDP concurrent postoperative radiotherapy in Chinese 
women with high- and intermediate-risk early cervical 
cancer. 
 
Material and Methods: Women with high risks postoperative 
cervical carcinoma, negative para-aortic nodes, KPS≥60 were 
eligible. Pelvis RT (6/10MV-X, 3D-CRT, DT40Gy/20f, para-
metrial boost 10~20Gy/5~10f) was followed by 2~4f 
brachytherapy applications (192Ir，5Gy/f). Concurrent 
weekly chemotherapy was started at DDP 20mg/m2/W and 
PTX 10mg/m2/W, and escalated in three-patient cohorts 
according to 3+3 methods. Serious Adverse Event (SAE) was 
defined as grade 4 hematologic toxicity (excluding anemia) 
within 30 days of treatment, or grade 3/4 non-hematologic 
toxicity (excluding alopecia, nausea/anorexia, vomiting). 




Results: 25 patients were enrolled and treated over seven 
doses levels until dose-limiting toxicity (DLT) was reached. 
Median age was 48 years (range, 34-66). All of patients 
finished RT in 6 weeks. Grade 3/4 non-hematologic toxicities 
were diarrhea and observed in two patients (4 cycles, DLT) at 
level VII. 3/4°hematologic, principally neutropenia, and 
occurs late cycles. One grade IV WBC and NEUT was observed 
at dose level VI but not seen in three additional patients. No 
one was delayed treatment time by concurrent 
chemotherapy. The 1st patient finished 3 cycles due to 2° 
diarrhea at level I; 1 patient for 5 cycles at level III; 4 
patients finished 6 cycles at level VII. Median follow-up is 56 
months. 2 recurrent or metastasis patients have died. 1 
patient has died of acute pneumonia (30.5 months). Late 
toxicities did not appear during follow-up. 
 
Conclusion: Combination PTX and DDP administered 
concurrently with pelvic EBRT can be safely administered at 
the MTD of DDP 35 mg/m2 and PTX 30 mg/m2 weekly for six 
cycles in Chinese women with postoperative cervical cancer. 
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Purpose or Objective: In order to verify the results in a 
population of patients (pts) staged with CT and MR and 
treated with HDR BT and modern EBRT techniques, we review 
our experience in the treatment of vaginal or pelvic 
recurrences of endometrial adenocarcinoma. 
 
Material and Methods: April 1997-October 2012 181 pts. 161 
(89%) endometrioid, 12 adenosquamous and 8 clear cell. 30% 
G1, 42% G2, 25% G3, 10% G unknown. Median age 70 years 
(range 41-83). First line treatment: surgery alone 134 pts, 
surgery plus EBRT 27 pts, surgery plus CTH 18 pts and EBRT 
alone 2 pts. TAH&BSO 145 (80%) pts (36 with pelvic lymph-
node sampling), Piver II and pelvic lymphadenectomy 36 pts. 
Median time to relapse 27 months (range 3-221). 126 pts had 
vaginal recurrences (66 limited to the dome and 60 with 
extension to the mid and/or lower third). 45 had a pelvic 
mass (31 centropelvic, 14 lateral wall); 10 pts had a vaginal 
recurrence with synchronous extra pelvic disease (6 lung mts 
and 4 LA nodes). 27 pts had prior adjuvant EBRT after 
surgery: dose range 32.4-57 Gy; no pts had received VBT. 
VBT: we use vaginal, shielded cylinders, Miami applicator and 
vaginal ovoid; interstitial BT in addition to VBT in 11 patients 
with sub urethral infiltration. HDR BT alone in 68 pts and in 
combination with EBRT in 113 pts. EBRT doses: range 30.6-
50.4 Gy. VBT HDR doses: range 15-25 Gy when used in 
combination with EBRT and 30-44 Gy when used alone; 
fraction size: range 4-6 Gy. Interstitial BT: 2-2.5 Gy fr, 2 
frs/day, total dose 20-25 Gy. Prescriptions for VBT were at 
depths ranging between 5 and 10 mm, according with the 
lesion size. 
 
Results: Clinical CR 170 pts (94%). Median f-up 102 months 
(range 32-168). 38 pts DOD (14 lung mts, 8 with peritoneal 
mts without local failure and 16 with local failure, peritoneal 
and/or lung mts); 18 AWD and 125 (69%) NED. 27 local 
recurrences: median time to relapse 20 months (range 5-36); 
we retread, 12 of these, with further VBT HDR and five 
achieved a new CR. Late complication: 98 pts (54%) G0, 45 
pts vaginal stenosis and/or severe mucosal dystrophy, 18 mild 
proctitis (G1), 5 severe proctitis (G2), 2 (G3) small bowel 
fistula that required surgery; 12 urine incontinence. Two 
developed a severe necrosis of the mucosa of the inferior 
third of the vagina that resolved after medical therapy. 
 
Conclusion: Treatment of local recurrences of endometrial 
adenocarcinoma in a population of pts staged with CT and MR 
and treated with HDR BT and modern EBRT is effective and 
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Purpose or Objective: Vaginal cancer is the most rare 
gynecological malignancy. Consequently, few dose effect 
data are available. The main objective of our retrospective 
study was to analyze the outcome of all patients treated at 
our department with definitive (chemo-)radiotherapy for 
primary vaginal cancer, with a focus on local failure. 
